The British In Vitro Diagnostics Association represents the IVD Industry in the UK, to Government, professional bodies, the public, and at the European Diagnostic Manufacturers Association.

Giving support to members on regulatory issues, BIVDA also promotes the clinical and cost utility of IVDs in the provision of effective healthcare, both in acute diagnosis and in the prediction and prevention of disease.

If you would like to become a BIVDA member and find out the multiple benefits then please visit -
Oxford Biosystems

Based in Milton Park, Oxfordshire, Oxford Biosystems was established in 2001 with the aim of sourcing reliable, quality in-vitro diagnostic products and research tools for clinical, industrial and research laboratories.

In 2009 the joining of Cadama Medical Ltd (founded in Birmingham, UK in 2002) with Oxford Biosystems brought together expertise in a wide variety of technologies including ELISA, IRMA, RIA, Real time PCR, EliSpot and Image analysis.

Oxford Biosystems are full members of BIVDA and company members of IBMS and are proud to hold ISO 9001:2015 certification.

Headquartered in Lexington, MA, for over 30 years Sekisui Diagnostics has been committed to helping improve the lives of patients by providing innovative medical diagnostics to physicians and laboratories. We have a history of innovation which includes, as examples, the first homogeneous test for LDL and the first plastic vacuum blood collection tube. We continue to invest in new products in the areas of diabetes, infectious disease, coagulation, diagnostic enzymes and automated systems, and have a leading position as a provider of rapid tests in the US and high throughput coagulation systems in Japan.

Sekisui Diagnostic’s workforce includes over 500 employees, in eight sites located in four countries. We are a sister company to Sekisui Medical in Japan and in China, making us a worldwide company with R&D and Manufacturing facilities on three continents.

We develop, manufacture, and supply billions of tests each year to the global healthcare market through our commercial networks and partners.

Our product lines include:
  • Clinical chemistry systems and reagents
  • Coagulation systems and reagents
  • Infectious disease rapid tests
  • Infectious disease rapid tests
  • Point of care immunoassay system
  • Enzymes and specialty biochemicals
  • Momentum BioScience

    Our team is made up of experienced and talented individuals who are determined and passionate about combating antimicrobial resistance.

    Founded in the UK to develop rapid tests for critically-important clinical specimens

    Founded in the UK to provide faster diagnostic assessment of patients suspected of bloodstream infections (BSI), a condition which can lead to deadly septic shock and requires accurate and immediate antibiotic therapy.

    CIGA Healthcare, specialists in In-Vitro Point of Care Diagnostics, aids healthcare in producing financial savings and improving patient pathways and experience through the provision of innovative rapid, easy to use and accurate point of care diagnostic tests and equipment.

    We look forward to meeting you at the UK Diagnostics Summit, in the meantime do visit our web site at
    Prospect Diagnostics

    Prospect Diagnostics Limited is a leading company in the supply, logistics and support of point of care medical diagnostic devices and consumables to the UK Healthcare sector.

    We value our relationships with our suppliers, and pride ourselves on the quality of our customer service through:
      - Partnership with leading diagnostics manufacturers and healthcare supplies worldwide
      - Always seeking to introduce innovative and effective diagnostic solutions
      - We supply and support over 5,000 'point of care' practitioners throughout the UK
      - We have a greater than 98.5% success record over 20 years in despatching goods on same day as receipt of order for next day delivery
      - We are a committed and accredited 'Investor in People' business
    Thermo Fisher

    Antibiotics can save lives, but their increasingly unwarranted use in healthcare is causing the growth of antimicrobial resistance. Thermo Fisher Scientific's B·R·A·H·M·S Procalcitonin can help to reduce unnecessary antibiotic prescriptions. B·R·A·H·M·S PCT assays have been demonstrated to improve the accuracy of diagnosis and risk assessment in bacterial infection and sepsis, and to guide antibiotic therapy-related decisions.

    Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support

    FebriDx® is the first and only rapid, point of care test that uses a capillary blood sample to identify and differentiate a clinically significant immune response to viral and/or bacterial acute febrile respiratory infection. The FebriDx® test detects elevated levels of Myxovirus resistance A (MxA) – a derivative of interferon that becomes elevated in the presence of acute viral infection, and C-reactive protein (CRP) – an acute phase protein that is elevated in the presence of bacterial infection.

    The FebriDx® test can be used to help triage infectious patients at the point of care, providing clinicians with a clear path to diagnosis and treatment, leading to more efficacious healthcare decisions. Test results are available in as soon as 15 minutes, allowing a treatment plan to be established during the patient’s initial surgery visit.

    For more information please click HERE
    Abbott (formerly Alere)

    ‘Through our vision of Knowing now matters™, Abbott delivers reliable and actionable information through rapid diagnostic tests, resulting in better clinical and economic healthcare outcomes. As a leader in the healthcare diagnostics field, Abbott are committed to delivering high quality products and services that patients and providers can rely on for consistently accurate and actionable information, using our easy-to-use and cost-effective tests. Our diagnostics make information available to providers and patients in actionable timeframes – streamlining healthcare delivery and improving patient outcomes. Come and see how point of care CRP testing can reduce unnecessary prescribing or visit
    Accelerate Diagnostics UK Ltd

    Accelerate Diagnostics UK Ltd is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and hospital acquired infections. The Accelerate PhenoTM system is the first to provide rapid identification and MIC- based susceptibility results, direct from sample, in hours instead of days - identification in about 90 minutes, antibiotic susceptibility 5 hours later-.

    These fast results will enable clinicians to make targeted, lifesaving therapy decisions 1- 2 days earlier. Ultimately, they will be able to optimize antimicrobial therapy sooner.

    For more information click HERE
    Johnson & Johnson

    About Johnson & Johnson Diabetes Care Companies (JJDCC) With a shared vision of creating a world without limits for people with diabetes, the Johnson & Johnson Diabetes Care Companies are a collaboration of Johnson & Johnson companies dedicated to diabetes and includes LifeScan, Inc., a world leader in blood glucose monitoring; Animas Corporation, maker of innovative insulin delivery systems; Calibra Medical, Inc. developer of OneTouch Via™ on-demand insulin delivery; and the Johnson & Johnson Diabetes Institute, LLC, a global initiative to improve care and better outcomes worldwide through education and training programs. Globally, more than 20 million people depend on OneTouch® brand products to help them manage their diabetes.

    For more information, visit:
    Atlas Genetics

    Atlas Genetics Ltd (AGL) is an innovative, UK-based diagnostics company. Atlas Genetics' io® Point-of-Care (POC) platform will revolutionise patient testing by providing clinicians and healthcare professionals with an accurate, actionable test result in 30 minutes. With an initial focus on Sexually Transmitted Infections, the io® platform allows clinicians to make informed treatment decisions in a single patient visit to a clinic, improving patient outcomes and reducing the spread of infection. The io® system comprises a small, low cost, easy to use instrument (io® Instrument) and a test-specific disposable (io® Cartridge).

    Media Partners

    Technology Networks

    Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters. Our global community is made up of over 300,000 researchers and scientific professionals from the life science, drug discovery and analytical arenas.

    Diagnostics (ISSN 2075-4418) is an international scholarly Open Access journal on medical diagnostics, including molecular diagnostics, nuclear medicine, medical imaging, biomarkers, clinical decision support systems, lab-on-a-chip, microfluidics and novel diagnostic devices.

    Please click here for more information


    To discuss sponsorship opportunities please contact
    Phone- 0161 484 5680